Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EBIT (2022 - 2025)

Bioregenx has reported EBIT over the past 4 years, most recently at -$935658.0 for Q4 2025.

  • For Q4 2025, EBIT rose 94.89% year-over-year to -$935658.0; the TTM value through Dec 2025 reached -$1.2 million, up 94.54%, while the annual FY2025 figure was -$1.2 million, 94.54% up from the prior year.
  • EBIT for Q4 2025 was -$935658.0 at Bioregenx, down from -$8459.0 in the prior quarter.
  • Over five years, EBIT peaked at -$2191.0 in Q3 2022 and troughed at -$18.3 million in Q4 2024.
  • A 4-year average of -$1.7 million and a median of -$202085.0 in 2023 define the central range for EBIT.
  • Biggest five-year swings in EBIT: crashed 112567.87% in 2023 and later surged 97.42% in 2025.
  • Year by year, EBIT stood at -$5535.0 in 2022, then tumbled by 3722.13% to -$211555.0 in 2023, then crashed by 8558.18% to -$18.3 million in 2024, then skyrocketed by 94.89% to -$935658.0 in 2025.
  • Business Quant data shows EBIT for BRGX at -$935658.0 in Q4 2025, -$8459.0 in Q3 2025, and -$107259.0 in Q2 2025.